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Genome wide association study of response
to interval and continuous exercise training:
the Predict‑HIIT study
Camilla J. Williams1†, Zhixiu Li2†, Nicholas Harvey3,4†, Rodney A. Lea4, Brendon J. Gurd5, Jacob T. Bonafiglia5,
Ioannis Papadimitriou6, Macsue Jacques6, Ilaria Croci1,7,20, Dorthe Stensvold7, Ulrik Wisloff1,7, Jenna L. Taylor1,
Trishan Gajanand1, Emily R. Cox1, Joyce S. Ramos1,8, Robert G. Fassett1, Jonathan P. Little9, Monique E. Francois9,
Christopher M. Hearon Jr10, Satyam Sarma10, Sylvan L. J. E. Janssen10,11, Emeline M. Van Craenenbroeck12,
Paul Beckers12, Véronique A. Cornelissen13, Erin J. Howden14, Shelley E. Keating1, Xu Yan6,15, David J. Bishop6,16,
Anja Bye7,17, Larisa M. Haupt4, Lyn R. Griffiths4, Kevin J. Ashton3, Matthew A. Brown18, Luciana Torquati19,
Nir Eynon6 and Jeff S. Coombes1*

Abstract
Background: Low cardiorespiratory fitness (V̇O2peak) is highly associated with chronic disease and mortality from
all causes. Whilst exercise training is recommended in health guidelines to improve V̇O2peak, there is considerable
inter-individual variability in the V̇O2peak response to the same dose of exercise. Understanding how genetic factors
contribute to V̇O2peak training response may improve personalisation of exercise programs. The aim of this study was
to identify genetic variants that are associated with the magnitude of V̇O2peak response following exercise training.
Methods: Participant change in objectively measured V̇O2peak from 18 different interventions was obtained from
a multi-centre study (Predict-HIIT). A genome-wide association study was completed (n = 507), and a polygenic
predictor score (PPS) was developed using alleles from single nucleotide polymorphisms (SNPs) significantly associated (P < 1 × 10–5) with the magnitude of V̇O2peak response. Findings were tested in an independent validation study
(n = 39) and compared to previous research.
Results: No variants at the genome-wide significance level were found after adjusting for key covariates (baseline
V̇O2peak, individual study, principal components which were significantly associated with the trait). A Quantile–Quantile plot indicates there was minor inflation in the study. Twelve novel loci showed a trend of association with V̇O2peak
response that reached suggestive significance (P < 1 × 10–5). The strongest association was found near the membrane
associated guanylate kinase, WW and PDZ domain containing 2 (MAGI2) gene (rs6959961, P = 2.61 × 10–7). A PPS created
from the 12 lead SNPs was unable to predict V̇O2peak response in a tenfold cross validation, or in an independent
(n = 39) validation study (P > 0.1). Significant correlations were found for beta coefficients of variants in the Predict-HIIT
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(P < 1 × 10–4) and the validation study (P <  × 10–6), indicating that general effects of the loci exist, and that with a
higher statistical power, more significant genetic associations may become apparent.
Conclusions: Ongoing research and validation of current and previous findings is needed to determine if genetics
does play a large role in V̇O2peak response variance, and whether genomic predictors for V̇O2peak response trainability can inform evidence-based clinical practice.
Trial registration Australian New Zealand Clinical Trials Registry (ANZCTR), Trial Id: ACTRN12618000501246, Date Registered: 06/04/2018, http://www.anzctr.org.au/Trial/Registration/TrialReview.aspx?id=374601&isReview=true.
Keywords: Genetics, V̇O2peak training response, Individual variability, GWAS, Polygenic predictor score

Background
Cardiorespiratory fitness (CRF) is measured by peak
oxygen uptake (V̇O2peak) during a graded exercise
test, and is strongly associated with a reduced risk of
cardiometabolic diseases and mortality [1]. Improving
V̇O2peak can generally be achieved by regular endurance exercise training, in a dose-dependent manner [2].
Data typically supports the notion that a higher dose
of exercise (volume and intensity) will elicit greater
V̇O2peak gains [3–7]. Interval training, such as sprint
interval training (SIT) and high-intensity interval training (HIIT) have shown comparable [8] and greater
[9–13] group mean V̇O2peak changes, respectively,
compared with moderate-intensity continuous training (MICT). However, there is considerable inter-individual variability in observed V̇O2peak improvements
following apparently similar exercise training [7, 14].
Identifying the genetic and environmental determinants that can predict exercise response may pave the
way to personalised exercise programs that can maximise health outcomes.
An early genome wide association study (GWAS) using
data from the HEalth, RIsk factors, exercise Training And
GEnetics (HERITAGE) Family Study reported that 21
variants contributed to 49% of the variance in V̇O2peak
response [15]. However, very few of these variants have
been replicated in further testing or other studies suggesting that the variants identified in the HERITAGE
study were overfitted to the specific population. In a
recent systematic review, we identified 35 studies describing 15 cohorts that found 97 possible variants associated
with V̇O2peak training response [16]. Only 13 genetic
variants were replicated by more than two authors [15,
17–25], and none reached genome-wide significance. A
lack of replication and significance in previous research
is mostly likely due to underpowered studies that have
predominantly been candidate-gene focused [26, 27].
Furthermore, a comparator arm is necessary to discriminate true inter-individual variability from random and
technical variability, yet very few studies included such a
group, nor did they investigate or control for population
stratification. This evidence to-date questions the validity

of using currently available commercial genetic tests to
prescribe exercise interventions.
Larger sample sizes are needed to build upon current
research and to overcome random error in V̇O2peak
measurement at the individual level. Greater collaboration between research centres using a discovery driven
approach free from pre-existing bias is warranted [26].
V̇O2peak response between different population groups
and training interventions along with assessing how individual factors modulate response, should also be explored
[28]. The aim of this study was to use one of the largest
cohorts to-date (multi-centre Predict-HIIT [7] study) to
complete a GWAS to investigate genetic variants associated with V̇O2peak response following exercise training
interventions. In addition, we attempted to replicate candidate variants from previous studies, and aimed to build
and validate a genetic prediction model for V̇O2peak
response (polygenic predictor score, PPS) based on the
genetic data.

Methods
Cohorts
Discovery cohort—‘Predict HIIT’

Predict-HIIT participant characteristics, recruiting and
study intervention details have been previously outlined
[7]. Ethical approval was obtained from the Bellberry ethical committee at the University of Queensland (#201602-062-A-1), and from all the institutions involved.
Participant data was collated from 18 exercise training
interventions across eight universities from three continents. As outlined in our previous paper [7], participant
change in objectively measured V̇O2peak (indirect calorimetry from a graded exercise test to volitional fatigue
on a treadmill or cycle ergometer) was obtained following
high-volume HIIT (sessions contained ≥ 15 min of highintensity efforts in total, n = 225), low-volume HIIT/SIT
(sessions contained < 15 min of high-intensity efforts in
total, n = 76), or MICT (sessions contained 30 + minutes
of continuous exercise at 64–76% maximum heart rate,
n = 206). The characteristics of the 507 participants from
predominantly European descent used in our GWAS are
outlined in Table 1 (24% female, age 55.9 ± 16.9 years,
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Table 1 Genome-wide association study participant characteristics. Mean ± standard deviation
High-volume HIIT

MICT

Low-volume HIIT/SIT

All

Participants

225

206

76

507

Sex (male/female)

187/38

156/50

42/34

385/122

Age (years)

53.4 ± 17.4

61.9 ± 12.2

46.6 ± 20.1

55.9 ± 16.9

Baseline relative V̇O2peak
(mL/kg/min)

32.1 ± 11.5

27.6 ± 8.1

30.4 ± 13.7

30.1 ± 10.8

Relative V̇O2peak response
(mL/kg/min)

3.4 ± 4.1
Range: − 6.5 to 18.4

2.9 ± 3.6
Range: − 7.4 to 15.3

1.9 ± 2.8
Range: − 4.6 to 8.8

*3.0 ± 3.8
Range: − 7.4 to 18.4

Number of ‘likely non
responders’ (> 1 TEM
below + MCID to < 1 TEM
below the –MCID)
Number of ‘Likely
responders’ (> 1 TEM
above the + MCID)
Number of ‘uncertain’
responders (< 1 TEM
above to < 1 TEM
below + MCID)

86 (38%)
V̇O2peak response = − 0.6 ± 1.9
(mL/kg/min)
PPS: 2.7 ± 2.2

82 (40%)
V̇O2peak response =
− 0.5 ± 1.9 (mL/kg/min)
PPS: 2.5 ± 2.2

67 (30%)
V̇O2peak response = 8.4 ± 2.8
(mL/kg/min)
PPS: 6.8 ± 3.7

43 (21%)
12 (16%)
**122 (24.1%)
V̇O2peak response = 8.0 ± 2.1 V̇O2peak response = 6.4 ± 0.9 V̇O2peak response = 8.1 ± 2.4
(mL/kg/min)
(mL/kg/min)
(mL/kg/min)
PPS: 6.3 ± 3.1
PPS: 4.8 ± 2.3
PPS: 6.4 ± 2.7

72 (32%)
V̇O2peak response = 3.6 ± 1.0
(mL/kg/min)
PPS: 3.5 ± 2.6

42 (55%)
V̇O2peak
response = − 0.1 ± 1.5
(mL/kg/min)
PPS: 2.4 ± 2.6

*210 (41.4%)
V̇O2peak
response = − 0.43 ± 1.9
(mL/kg/min)
PPS: 2.5 ± 2.3

82 (39%)
22 (29%)
175 (34.5%)
V̇O2peak response = 3.5 ± 3.6 V̇O2peak response = 3.1 ± 1.0 V̇O2peak response = 3.5 ± 0.99
(mL/kg/min)
(mL/kg/min)
(mL/kg/min)
PPS: 3.4 ± 2.9
PPS: 3.5 ± 0.9
PPS: 3.5 ± 3.1

TEMs were slightly different for each training intervention and have been outlined in Table 3
Technical error of measurement (TEM) = multiplying mean V̇O2peak value by a previously published coefficient of variation for V̇O2peak of 5.6%, Minimal Clinically
Important Difference (MCID) = 3.5 mL/kg/min, Polygenic Predictor Score (PPS). *Significant difference between high-volume HIIT & low-volume HIIT/SIT (P < 0.05),
**

Significant difference between high-volume HIIT, MICT & low-volume HIIT/SIT (P < 0.05)

83% with pathologies and/or elderly). The deoxyribonucleic acid (DNA) extraction, preparation and genotyping are outlined below. These details varied based on the
study site where the sample was collected, and whether
DNA extraction and/or genotyping had already been
completed prior to this study. Our quality control measures have limited bias associated with different DNA
preparation, extraction methods and genotyping.
Validation cohort—‘Improve‑HIIT’

For replication of our results, we utilised the unpublished findings from an independent study recently
performed in our laboratory (Improve-HIIT). The
‘Improve-HIIT’ study examined the response to highvolume HIIT by randomly allocating 40 sedentary
(< 1 h of structured exercise each week) but apparently healthy Caucasian adults (age 18–50) to one of
two groups: (i) 6 weeks of supervised high-volume
HIIT (5 min warm up, 4 min 90–95% heart rate maximum followed by 3 min recovery repeated 4 times, 3×/
week) + prebiotic fibre (oligofructose-enriched inulin)
supplementation (12 g/day) or (ii) 6 weeks of supervised
high-volume HIIT (3×/week) + placebo (maltodextrin)
supplementation (12 g/day). There was no difference in
the average V̇O2peak response, or the inter-individual
variability in V̇O2peak response between study groups;

as such, this study was deemed appropriate for validating findings from the Predict-HIIT GWAS. Ethical
approval was obtained from the Institutional Human
Research Ethics Approval committee at the University
of Queensland (#2018000398).
Each participant completed a series of tests and several measures were collated before and after the intervention. Tests relevant to this analysis included the
completion of an incremental V̇O2peak test to exhaustion on a treadmill (Ramped Bruce Protocol) using
indirect calorimetry (Parvo Medica True One 2400 System, Parvo Medics, Inc., Sandy, UT, USA) before and
after the intervention period, and provision of a saliva
sample for genetic analysis (Oragene DNA collection
kit, DNA Genotek, Ontario, Canada).
Genotyping, imputation and quality control were
completed with the same protocol as for the PredictHIIT cohort. One sample was removed due to high
missing genotyping rate, leaving 39 samples for further analysis. V̇O2peak response (post intervention
V̇O2peak—pre intervention V̇O2peak) was calculated
for each participant. Fibre/placebo supplement, age,
sex, body fat percentage and baseline V̇O2peak were
not correlated with response and were not included as
covariates for analysis. Using PLINK, the top ranked
loci (P < 1 × 10−5) from the Predict-HIIT study were
compared in the Improve-HIIT study. Lower ranking
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Table 2 Validation study (Improve-HIIT) participant characteristics. Mean ± standard deviation
Intervention

Age (years)

Sex (M = male, F = female)

Baseline V̇O2peak
(mL/kg/min)

V̇O2peak
response (mL/
kg/min)

8 weeks of maltodextrin + 6 weeks of high-volume HIIT

30.4 ± 9.8

4 M, 16 F (20 Total)

32.8 ± 9.8

5 M, 14 F (19 Total)

29.3 ± 7.4

3.7 ± 4.7

Total

31.6 ± 9.8

9 M, 30 F (39 Total)

32.4 ± 7.1

3.8 ± 5.0

8 weeks of oligo-fructose enriched inulin + 6 weeks of
high-volume HIIT

loci (P < 1 × 10−4) were also examined between cohorts
(see Table 2 for study characteristics).
DNA preparation
DNA extraction from whole blood

Genomic DNA from 58 whole blood samples [29] was
extracted using a QIAamp DNA blood midi kit (Qiagen, Hilden, Germany) according to the manufacturer’s
instructions. The DNA samples were quantified using
a Qubit fluorometer 3.0 and all samples were diluted to
100 ng/µL for genotyping.
DNA extraction from buffy coat

DNA from 93 buffy coats [30] was extracted using a
QIAsymphony DSP DNA Mini Kit according to manufacturer’s instructions [31]. The purified genomic DNA
was stored at −20 degrees until genotyped.
DNA extraction from saliva samples

DNA from 289 saliva samples from two studies [32, 33]
were extracted using a QIAsymphony (Qiagen) DNA
MIDI Kit according to manufacturer’s instructions.
The yield and purity were measured using a Trinean
DropSense-96. DNA from a further 93 saliva samples
from 10 studies [34–43] were extracted using the protocol outlined on the DNA Genotek website [44].
Genotyping

DNA from 417 samples [29, 30, 32, 34–43] were genotyped using Illumina CoreExome chips 24v1.1 following standard protocols at the Australian Translational
Genomics Centre, Princess Alexandra Hospital, Brisbane.
A further 116 samples from Norway [33] were genotyped
using Illumina CoreExome chips 24v1.2 at the Genomics
Core Facility, NTNU. Bead intensity data was processed
and normalised for each sample, and genotypes were
identified using the Illumina Genome Studio software
with corresponding manifest files. SNP coordinates were
annotated to the GRCh37 genome build.
Data quality control

Genotypes at individual SNPs from all cohorts were
merged according to the manifest and plink files. Quality

35.6 ± 5.3

3.9 ± 5.3

control was completed separately on individual cohorts,
and included assessment of missingness by individual
(threshold < 5%), missingness by genotype (threshold < 5%), Hardy–Weinberg equilibrium in controls
(P < 1 × 10−6), extreme heterozygosity (threshold > 3
standard deviations from mean) and identity by descent
threshold at 0.2 of PI_HAT score (n = 13 excluded
individuals). For each pair of related samples (PI_
HAT > threshold), the sample with the higher missingness
rate was removed (n = 3 excluded individuals). Along
with quantitative GWAS analysis, we further defined
groups based on their relative change in V̇O2peak (mL/
kg/min) for additional comparisons. Samples were classified as a ‘likely-responder’, ‘likely non-responder/adverse
responder’ and ‘uncertain responder’ based on their relative change in V̇O2peak (mL/kg/min) following training. As outlined in Williams et al. [7], a likely responder
achieved a V̇O2peak response above one minimal clinically important difference (3.5 mL/kg/min) associated
with a 10–25% improvement in survival over a 10-year
period, plus one technical error of measurement (average baseline V̇O2peak multiplied by coefficient variation
of 5.6%; calculated for each study). This high threshold
for response was used to increase the confidence in the
‘likely responder’/’likely non-responder’ classification.
The thresholds are provided in Table 3.
SNPs with Minor Allele Frequency (MAF) > 0.05
were then used to perform principal component analysis (PCA) for ethnicity identification using SHELLFISH
[45]. Ethnic and ancestry outliers (more than 6 standard
deviations from the mean on either of the two first principal components (PCs)) were excluded (n = 10). Then,
data was imputed with the Haplotype Reference Consortium (HRC) reference panel 1.1 [45] using the Sanger
imputation server. SNPs with low imputation quality
(INFO score ≤ 0.6) were excluded from further analysis.
In total, 26 samples were removed due to large ethnicity
deviations from the group, leaving 507 samples for association testing (Table 1). Genomic inflation factor λ and
quantile–quantile (Q–Q) plots were used to compare the
genome-wide distribution of the test statistic with the
expected null distribution. The genomic inflation factor
λ is defined as the median of the observed chi-squared
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Table 3 Thresholds for response
Category

Criteria

Likely responder

> 1 TEM above the + MCID

Likely non-responder
Uncertain responders

High-volume HIIT
(mL/kg/min)

> 1 TEM below + MCID to < 1 TEM below the –MCID

< 1 TEM above to < 1 TEM below + MCID

MICT (mL/kg/min)

Low-volume
HIIT/SIT (mL/kg/
min)

> 5.3

> 5.0

> 5.2

− 5.3 to 1.7

− 5.0 to 2.0

− 5.2 to 1.8

1.7 to 5.3

2.0 to 5.0

1.8 to 5.2

Technical error of measurement (TEM) = multiplying mean V̇O2peak value by a previously published coefficient of variation for V̇O2peak of 5.6%,

Minimal Clinically Important Difference (MCID) = 3.5 mL/kg/min

test statistic divided by the expected median of the corresponding chi-squared distribution. A λ close to 1
reflects no evidence of inflation, while values up to 1.10
are generally considered acceptable for a GWAS. Baseline
V̇O2peak, the individual study and PC6 (the 6th principal
components from the PCA analysis, which was significantly associated with the phenotype) were included as
covariates.

imputed lead SNP, were checked manually to eliminate
poor signals. An analysis of covariance was used to compare the average V̇O2peak response for each genotype of
the top-ranked SNPs, including baseline V̇O2peak, the
individual study and PC6 as covariates. Statistical analysis was completed using SPSS (version 23.0, SPSS Inc.,
Chicago, IL, USA).

Statistical analysis
V̇O2peak response

A polygenic predictor score (PPS) was calculated for
each participant using the beta coefficient of the selected
SNPs. The PPS was an extension of the ‘summary predictor score’ outlined by Bouchard et al. [15] using data
from the HERITAGE study. In our study, we sought to
improve on this model to ensure the ‘high response training alleles’/‘effect’ alleles were weighted by the effect size
(beta coefficient) derived from our GWAS (see Eq. 1).

Normality for V̇O2peak was assessed using the Shapiro–
Wilk test. An analysis of variance was used to compare
average group V̇O2peak response between training interventions (high-volume HIIT, MICT, low-volume HIIT/
SIT). Variability in response was measured by the range
of responses for each intervention. A chi-squared test
was used to compare the proportion of likely responders,
likely non-responders and those participants classified as
uncertain between training groups.
Association testing of independent V̇O2peak responses

Similar to previous studies in this area [15] investigating
polygenic phenotypes (i.e. V̇O2peak trainability), we used
a quantitative approach rather than a case–control analysis to identify variants associated with V̇O2peak response.
Association testing was conducted in PLINK [46], using
a linear regression. Baseline V̇O2peak, the individual
study and the PC6 from the principal component analysis
were found to be significantly associated with V̇O2peak
response and were included as covariates in analysis.
Age and sex were not associated with the trait. Our findings did not change when age and sex were also included
in the association analysis. Thus, we included covariates based on a posteriori instead of a priori knowledge.
Association analyses of imputed SNPs was assessed with
PLINK best-guess genotypes. Genome-wide significance
was set at the standard GWAS threshold of P < 5 × 10−8
and suggestive significance was set at P < 1 × 10−5. The
single most significant SNP (the lead SNP) was used
to represent each of the loci. The cluster plots of the
genotyped lead SNP, or supported genotyped SNPs of

Polygenic predictor score

PPS =

k


βi ∗ ni

(1)

i

where i is the index of the SNP in k selected SNPs used
to calculate the PPS. βi is the effect size (beta coefficient
of linear regression) of SNPi in the PPS model, ni is the
number of effect alleles of SNPi.
Scores were then added across k SNPs to yield a final
PPS and a comparison was made between likely responders, likely non-responders and those deemed uncertain
(as described earlier). To avoid over-training (inability
of model to be generalised to new data), we did a tenfold
cross-validation (using MultiBLUP [47]) with the discovery cohort samples and merged the results of 10 test
folds for the analysis. The tenfold cross validation was to
test the PPS model’s ability to predict V̇O2peak response
in new data not related to the development of the PPS
model internally.
Replication of candidate loci

The 97 loci identified as candidate
response in our recent systematic
analysed and compared with the
(α < 1 × 10−5) from the Predict-HIIT

loci for V̇O2peak
review [16] were
top-ranking loci
study. Lead SNPs
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from all associated loci were used to calculate the PPS,
as well as the 97 genetic variants found previously, were
mapped to the nearest gene and submitted as a batch
query to the ToppGene pathway analysis software [48].
Biological processes and pathways that appeared in both
groups were selected. Genetic variants were also submitted to the GTEx Portal to identify if any SNPs were
expressive quantitative trait loci (eQTL) [49].
Power calculation

Power calculations were performed using the Genomewide Complex Trait Analysis—Genomic-RelatednessBased Restricted Maximum Likelihood (GCTA-GREML)
calculator [50].

Results
V̇O2peak response was normally distributed. Participants
included in the GWAS from high-volume HIIT interventions had a greater V̇O2peak response at the group level
than participants from a low-volume HIIT/SIT intervention (1.6 mL/kg/min, 95% CI 0.6 to 2.5, P = 0.002), but
a comparable group V̇O2peak response to participants
from MICT interventions (0.6 mL/kg/min, 95% CI − 0.1
to 1.3, P = 0.1). Participants from MICT and low-volume
HIIT/SIT interventions had similar group responses
(1.0 mL/kg/min, 95% CI − 0.1 to 2.0, P = 0.05). Despite
these group mean changes, there was large variability
in individual V̇O2peak training response within each
intervention (see Fig. 1 and Table 1 for ranges). Highvolume HIIT had more likely responders than MICT
(9%, 0.7 to 17.0, P = 0.03) and low-volume HIIT/SIT
(14%, 2.7 to 23.1, P = 0.02). However, high-volume HIIT
had similar likely non-responders to MICT (− 2%, 95%
CI − 7.2 to 11.1, P = 0.7) and less likely non-responders

to low-volume HIIT/SIT (− 17%, 95% CI − 4.1 to − 29.3,
P = 0.01). Furthermore, high-volume HIIT had similar uncertain responders to MICT (− 7%, 95% CI − 2.0
to 15.9, P = 0.1) and low-volume HIIT/SIT (3%, − 9.4
to 14.0, P = 0.6). To establish the genetic contribution towards this variance in response to each exercise
training intervention, we completed a GWAS that was
adjusted for significant covariates (individual study that
the participant completed, baseline V̇O2peak and PC6).
No SNPs reached the typical threshold for genomewide significance (P < 5 × 10–8). The Q-Q plot and a
genomic inflation factor of 1.002 indicated there was very
minor inflation in the study (i.e. population stratification or DNA sample quality), and minor overdispersions
of test statistics when compared to the null distribution (Fig. 2). Twelve loci were associated with V̇O2peak
response at suggestive significance (P < 1 × 10–5, Fig. 3
and Table 4). The most significant association was found
for rs6959961 near the membrane associated guanylate
kinase, WW and PDZ domain containing 2 (MAGI2) gene
(P = 2.61 × 10–7). Homozygotes for the response allele
(TT, n = 93) had a 2.4 mL/kg/min greater (P = 2.8 × 10–7)
average V̇O2peak response than those homozygote for
the non-response allele (CC, n = 152) and a 1.3 mL/
kg/min greater (P = 0.002) average V̇O2peak response
than heterozygotes (TC, n = 262). The second most
significant association (P = 2.75 × 10–7) was found for
rs730747755 near the Unc-80 Homolog, NALCN Channel
Complex Subunit (UNC80) gene. Homozygotes for the
response allele (AA, n = 66) had a 2.6 mL/kg/min greater
(P = 1.2 × 10–7) average V̇O2peak response than those
homozygote for the non-response allele (GG, n = 229),
and a 1.8 mL/kg/min greater (P = 2.5 × 10–4) average
V̇O2peak response than heterozygotes (AG, n = 212).

VO2peak response (mL/kg/min)

20

15

High-volume HIIT

Low-volume HIIT/SIT

10

5

0

-5

Whole Cohort (n=507)

-10

Fig. 1 Variability in V̇O2peak response between participants included in the GWAS

MICT
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Fig. 2 Quantile–Quantile (QQ) plot and genomic inflation factor λ.
λ is the observed median of test statistic distribution divided by the
expected median of the test statistic distribution. A genomic inflation
factor greater than 1.1 indicates there may be some inflation of the
GWAS P-values; resulting from factors such as population stratification
or DNA sample quality. λ = lambda, base = baseline VO2peak,
study = individual study participant completed, PC6 = 6th principal
component

A tenfold cross validation found the Pearson correlation coefficient between subject polygenic predictor
score (PPS) and V̇O2peak response (likely responder,
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likely non responder or uncertain) was not significant
(R2 = 0.027, P-value = 0.76, see Fig. 4). Similarly, the
PPS was not able to predict V̇O2peak training response
in the validation (Improve-HIIT) cohort (R2 = 0.001,
P = 0.8). None of the 12 lead SNPs from our GWAS had
a P-value < 0.05 in the Improve-HIIT study. Furthermore, from the 992 variants with a P-value < 1 × 10–4
in the Predict-HIIT cohort, a correlation of beta coefficients in the discovery (Predict-HIIT) cohort and
the Improve-HIIT cohort was found to be significant
(R2 = 0.156, P-value = 7.62 × 10–7). This suggests these
variants in the Improve-HIIT cohort have a significant
similar trend of effect as they do in the Predict-HIIT
cohort.
Whilst none of the 12 lead SNPs from our GWAS validated SNPs found in previous research, several of our
lead 12 SNPs were found near genes that are in similar
biological pathways and processes to predictor genes
found in previous research (Table 5). Additionally, we
were able to validate a number of SNPs from previous
research at a nominal level (4 SNPs at P-value < 0.05,
see Table 6). Furthermore, we found several SNPs to
be eQTL in tissues that may influence training adaptations. For example, rs11647343, is an eQTL of zinc
finger DHHC-type palmitoyltransferase 7(ZDHHC7)
in whole blood (P = 1.8 × 10–5). The SNP, rs2657147, is

Fig. 3 Manhattan Plot of whole Training Cohort. The X-axis represents genomic coordinates, with the negative logarithm of the association p-value
for each variant displayed on the Y-axis. Different chromosomes are shown with different colours. The blue line indicates the suggestive significance
threshold 1 × 10–5

Williams et al. J Biomed Sci

(2021) 28:37

Page 8 of 15

Table 4 Lead SNP at each locus showing a trend for association with V̇O2peak response
SNP

CHR BP

P-value

210627971 2.75 × 10–7

BETA
1.17

Closet Gene

Effect allele Other allele MAF

UNC80
Unc-80 Homolog, NALCN Channel Complex Subunit

A

G

0.34

A

G

0.12

rs73074755

2

rs16875411

5

rs2236368

6

41309353 4.27 × 10–6

1.97

TFEB
Transcription Factor EB

A

G

0.068

rs111346648

7

2322104 4.86 × 10–6

3.27

AMZ1
Archaelysin Family Metallopeptidase 1

G

A

0.026

rs6959961

7

79297997 2.61 × 10–7

1.19

MAGI2
Membrane Associated Guanylate Kinase, WW And PDZ
Domain Containing 2

T

C

0.44

rs2657147

11

G

A

0.37

5359876 1.22 × 10–6 − 1.56 ADAMTS16
A Disintegrin-Like And Metalloprotease (Reprolysin Type)
With Thrombospondin Type 1 Motif, 16

4573236 4.08 × 10–6 − 1.08 OR52M1
Olfactory Receptor Family 52 Subfamily M Member 1

rs145056992 11

23069615 2.92 × 10–6

2.89

CCDC179
Coiled-Coil Domain Containing 179

G

A

0.036

rs79687662

15

92921291 1.85 × 10–6

2.33

IQGAP1
IQ Motif Containing GTPase Activating Protein 1

C

T

0.052

rs11647343

16

84454267 3.10 × 10–6

1.12

C

A

0.32

rs11874598

18

11064859 4.02 × 10–6

1.02

ATP2C2
ATPase Secretory Pathway Ca2 + Transporting 2

PIEZO2
Piezo Type Mechanosensitive Ion Channel Component 2

C

T

0.47

rs149323705 20

30964328 4.52 × 10–6

4.42

ASXL1
Additional Sex Combs Like 1, Transcriptional Regulator

T

C

0.014

rs73193458

33375476 3.13 × 10–6

1.49

CLDN14
Claudin 14

A

G

0.14

21

Genome build GRCH37, chromosome (CHR), single nucleotide polymorphism (SNP), physical position (BP), odds ratio (OR), responder/non-responder allele (A1),
minor allele frequency (MAF)

an eQTL of tripartite motif containing 68 (TRIM68) in
subcutaneous adipose tissue (P = 4.8 × 10–8).
The GCTA power calculator found a cohort of 2960
samples would have 80% power to detect a quantitative
trait with a true heritability of 30%.

Discussion
To our knowledge this is one of the largest multi-centre
GWAS to investigate CRF response following exercise
training. Compared to previous genetic studies in this
field of research, we were able to user newer technology and methodologies that increased the validity and
accuracy of our results. Across the 507 participants and
irrespective of the intervention completed, there was
large variability in individual V̇O2peak response to highvolume HIIT, MICT and low-volume HIIT/SIT. We were
unable to identify genetic variants at a genome-wide significant level that explained this variability in response to
each training intervention. However, 12 SNPs were found
at a suggestive level of significance and warranted further
investigation. Several of our lead SNPs seemed possible
candidate genes for predicting V̇O2peak response due
to their association with previously identified predictor

genes, and related biological pathways and processes that
may influence training adaptations.
The most significantly associated SNP, MAGI2, can
influence neuronal cell activin-mediated signalling,
and may supress AKT Serine/Threoine Kinase 1 (AKT1)
activation [51]. AKT1 is a V̇O2peak response predictor gene identified from previous research, and is one
of three genes from the protein kinase B family that
can influence growth, differentiation and metabolism
[52]. The SNP, rs1130214, found near AKT1, was significantly associated (P < 0.05) with V̇O2peak response
in previous research [52] and was found at a nominal
level in our Predict-HIIT cohort (P = 0.06). One of our
lead SNPs, rs79687662, is found near the IQ Motif Containing GTPase Activating Protein 1 (IQGAP1) gene.
IQGAP1 and AKT1 genes are both found in the E-cadherin signalling in the nascent adherens junction biological pathway, and together with Transcription Factor
Hypoxia-Inducible Factor-1 (HIF1A) and Neuropilin 2
(NRP2) (predictor genes from previous research), are
found in the signalling events mediated by the Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)
and Vascular Endothelial Growth Factor Receptor 2
(VEGFR2) biological pathway. Furthermore, a rat model
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Fig. 4 Tenfold cross validation—no correlation between Polygenic Predictor Score (PPS) and V̇O2peak response (R2 = 0.027, P = 0.76). Red, green
and blue dots represent likely non-responders, likely responders and uncertain responders, respectively

found the catenin (cadherin-associated protein) gene
was upregulated in higher responders to HIIT, which
helps to regulate angiogenesis, neurogenesis and tissue
development [53]. Another recent rodent study found
loss of Iqgap1 may lead to defective AKT and Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) signalling
and impaired cardiomyocyte hypertrophy [54].
Our second strongest associated lead SNP,
rs730747755, is found near the Unc-80 Homolog, NALCN
Channel Complex Subunit (UNC80) gene. UNC80 is a
gene that contributes to a large ion channel complex (the
‘NALCN channelosome”), which includes the Sodium
Leak Channel, Non Selective (NALCN) gene [55]. NALCN
is a V̇O2peak response predictor gene found in previous
research [18], and similar to the UNC80 gene, may influence the resting membrane potential of neuronal cells

[55]. There is evidence that genes encoding the NALCN
channelosome may contribute to the susceptibility for
several diseases, including cardiac diseases, some cancers
and psychiatric disorders [56].
Two of our associated lead SNPs were found near
genes related to peroxisome proliferator-activated
(PPAR) activity. The SNP rs14932370 is found near
the ASXL Transcriptional Regulator 1 (ASXL1) gene.
Overexpression of ASXL1 may reduce adipogenesis by
decreasing Peroxisome Proliferator-Activated Receptor
y (PPARy) activity [57]. The SNP, rs2236368, is found
near the Transcription Factor EB (TFEB) gene. TFEB
may regulate mitophagy, and in addition to Peroxisome
Proliferator-Activated Receptor Gamma, Coactivator 1
alpha (PGC-1α), is considered important for mitochondrial biogenic regulation [58]. TFEB may also regulate
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Table 5 Gene interactions and common biological pathways and processes between this study and previous findings
Biological pathways

P-value

Genes from input

Signaling events mediated by VEGFR1 and VEGFR2

2.31 × 10–4

HIF1A, IQGAP1, NRP2, AKT1

1.05 × 10–2

IQGAP1, AKT1

3.76 × 10–3

Cell adhesion molecules (CAMs)
E-cadherin signaling in the nascent adherens junction

CLDN14, NLGN1, ITGB8 CD6

Top 10 biological processes

P-value

Genes from input

Ion transport

3.24 × 10–6 KCNH8, ENPP3, GRIK4, NLGN1, PPARD, NR3C1, APOE, ACE, RYR2, ACSL1, PIEZO2,
SHANK2, KCNQ5, NALCN, KCNF1, SLC22A3, ATP2C2, AKT1, PRKG1, GRIN3A,
SLC45A1, KCNT1, UNC80

Growth

6.25 × 10–6 HIF1A, NDN, PPARD, NR3C1, APOE, ACVR1C, TTN, IQGAP1, NRP2, MAGI2, SHANK2,
RPTOR, CD44, AKT1, PRKG1, H19, CNTF

Developmental growth

7.08 × 10–6 NDN, PPARD, NR3C1, APOE, ACVR1C, TTN, IQGAP1, NRP2, MAGI2, SHANK2, AKT1,
PRKG1, H19, CNTF

Regulation of cell population proliferation

8.22 × 10–6 HIF1A, ENPP3, NDN, BIRC7, PPARD, NR3C1, APOE, ACVR1C, ACE, NRP2, FABP6,
PRDM1, GSTP1, MAGI2, CD6, RPTOR, CD44, PINX1, AKT1, PRKG1, H19, CNTF

Regulation of membrane potential

8.64 × 10–6 KCNH8, GRIK4, NLGN1, RYR2, PIEZO2, SHANK2, NALCN, AKT1, GRIN3A, KCNT1,
CNTF

Response to oxygen-containing compound

9.78 × 10–6 HDAC9, ASXL1, HIF1A, HLCS, ID3, CAT, PPARD, NR3C1, APOE, ACVR1C, ACE, ADCY5,
RYR2, IQGAP1, PRDM1, ACSL1, GSTP1, CD6, RPTOR, AKT1, GRIN3A

cation transmembrane transport

1.53 × 10–5 KCNH8, GRIK4, NLGN1, RYR2, PIEZO2, SHANK2, KCNQ5, NALCN, KCNF1, SLC22A3,
ATP2C2, PRKG1, GRIN3A, SLC45A1, KCNT1, UNC80

Cation transport

1.63 × 10–5 KCNH8, GRIK4, NLGN1, ACE, RYR2, PIEZO2, SHANK2, KCNQ5, NALCN, KCNF1,
SLC22A3, ATP2C2, AKT1, PRKG1, GRIN3A, SLC45A1, KCNT1, UNC80

Neurogenesis

1.85 × 10–5 HDAC9, HIF1A, ID3, NDN, NLGN1, NR3C1, APOE, IGQAP1, NRP2, PRDM1, YTHDF1,
MAGI2, SHANK2, DBX1, CD44, AKT1, PRKG1, GRIN3A, CNTF, ACE, GSTP1

Neuron differentiation

1.93 × 10–5 HDAC9, HIF1A, ID3, NDN, NLGN1, NR3C1, APOE, IGQAP1, NRP2, PRDM1, YTHDF1,
MAGI2, SHANK2, DBX1, CD44, AKT1, PRKG1, GRIN3A, CNTF

Bolded genes from input from the Predict-HIIT cohort. All other genes from previous research

Table 6 Findings from previous studies found significant at a nominal level in the Predict HIIT study
SNP

Closest gene

CHR Beta coefficient P-value in
Predict -HIIT
cohort

Author

Responder allele/
non-responder
allele in previous
research

Responder allele/nonresponder allele in
Predict-HIIT study

11

0.62

0.02

Gosh et al. [18]

Unknown

T allele (+)

rs10921078 RGS18
regulator of G protein
signaling 18

1

0.68

0.02

Bouchard et al. [15] G allele (−)

G (−)

rs1535628

GRIN3A
glutamate ionotropic
receptor NMDA type
subunit 3A

9

1.01

0.02

Bouchard et al. [15] Unknown

A (+)

rs2003298

NLGN1
neuroligin 1

2

0.47

0.04

Bouchard et al. [15] A allele (+)

T (+)

rs10751308 SHANK2
SH3 and multiple
ankyrin repeat
domains 2

CHR, Chromosome; SNP, single nucleotide polymorphism

insulin sensitivity, glucose homeostasis and lipid oxidation [59]. Overexpression of TFEB may increase mitochondrial biogenesis and ATP production in skeletal
muscle, independently from PCG-1α [59]. A study also
found PGC-1α expression can be increased through

the dephosphorylation and nuclear translocation of
TFEB [60]. With these points in mind, a recent study
found completing two high-intensity exercise sessions
within a short time frame (2 h) increased the nuclear
abundance of TFEB and the transcription of PCG-1α
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in 8 healthy young men [61]. Furthermore, overexpression of PGC-1α has been associated with improved
V̇O2peak at baseline and following endurance training
in several studies [62, 63].
Several of our other associated SNPs are found in the
same biological processes and pathways to variants identified in previous research [16]. The SNP rs73193458 is
found near the Claudin 14 (CLDN14) gene, and together
with previously identified V̇O2peak response predictor genes (Neuroligin 1 (NLGN1), Integrin Subunit Beta
8 (ITGB8) and Cluster of Differentiation 6 (CD6)) is
involved in the cell adhesion molecules (CAMs) biological pathway. The SNP rs11874598 found near the
Piezo Type Mechanosensitive Ion Channel Component 2
(PEIZO2) gene (which is a mechanosensitive ion channel involved in touch, proprioception, and respiratory
function [64]); and rs11647343 found near the ATPase
Secretory Pathway Ca2 + Transporting 2 (ATP2C2) gene
(which is related to nucleotide binding and calcium transporting ATPase activity and cardiac conduction [64]);
along with several other genes identified from previous
studies, are involved in cation transmembrane transport biological processes. We also found rs11647343 and
rs2657147 to be eQTLs of genes associated with whole
blood (ZDHHC7) and subcutaneous tissue (TRIM68),
respectively [49]. In mice, ZDHHC7 plays a role in glucose transporter type 4 (Glut4) palmitoylation, contributing to glucose homeostasis [65], possibly contributing
to metabolic adaptions required for V̇O2peak improvements. TRIM68 variants have been associated with early
onset obesity [66] and is upregulated following aerobic
exercise [67]. TRIM68 is associated with ubiquitination
[67] and may potentially play a role in proteolytic activity and exercise induced muscle damage. Body composition has been associated with exercise capacity, including
maximal workload and oxygen uptake [68, 69]. However,
more work is needed to go beyond association and to
identify causal variants/genes. Future functional studies
are needed.
Validation

We created a PPS from the top-12 associated loci from
the discovery cohort to identify who was more likely to
be a responder or non-responder to different forms of
training. It was hypothesised that those identified as a
lower responder may need a greater training dose than
reported in our study to elicit a clinically meaningful
response, or other environmental influences may need
to be considered. For example, Montero and Lundby [4]
have shown non-responders can become responders by
increasing the dose of exercise training. Despite many of
the suggestively associated SNPs showing a strong connection to previously identified genes, processes and
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pathways that may influence training adaptions to exercise, there was no significant correlation between the PPS
score and V̇O2peak response following the tenfold crossvalidation. The variants and model could not accurately
explain the variance in V̇O2peak response or predict who
may be a lower or higher responder to each of the training interventions. Likewise, an independent cohort validation, from the Improve-HIIT study, did not support an
association of the lead 12 SNPs with variance in V̇O2peak
response when considered individually, or in the PPS
model. This may be due to a relatively small sample size,
or in fact that genetics plays a smaller role than previous
research has alluded to. Our power calculation found we
need at least 2960 samples to detect signals of common
variants with a heritability of 30%.
Additionally, we were unable to replicate variants
(V̇O2peak response predictor genes) identified from previous research [16] at a genome wide or suggestive level
of significance. However, we were able to replicate several genetic variants from previous research at a nominal significance level within the Predict-HIIT cohort,
including: rs10751308, rs10921078, rs1535628 and
rs2003298 (P < 0.05). Two of these SNPs (rs10921078 and
rs2003298) had the same ‘response’ allele in the PredictHIIT cohort and previous research [15]. These SNPs
warrant investigation in future studies. Furthermore, a
significant Pearson correlation coefficient was found for
the beta coefficient of variants with a P-value < 1 × 10–4 in
the Predict-HIIT cohort the Improve-HIIT cohort. This
indicates general effects of the loci (as a group) exist, and
a larger sample size may detect many of these effects as
statistically significant.

Limitations
Several limitations may have prevented the finding of
more significant associations and validating the proposed
PPS model. Firstly, V̇O2peak response is considered a
complex trait that may result from multiple interactions between genes (epistasis) and epigenetic changes
that can affect gene expression [27]. This was made evident with several of the lead Predict-HIIT SNPs sharing
common biological pathways and processes to predictor
genes identified from previous studies. Larger sample
sizes than reported in our study (tens of thousands) are
often needed to investigate these gene interactions via a
GWAS, and to identify rare variants that may be contributing to overall response [70, 71]. A lack of detail in previous publications prevented some select variants from
being replicated. Previous studies have predominantly
been candidate-gene focused, and similar to our study,
have lacked the necessary statistical power [16]. The validation study also lacked statistical power and the population studied was different to the Predict-HIIT study.
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The Predict-HIIT study included a mix of healthy, young,
older and clinical European population groups from studies with a variety of exercise doses; whereas the validation
study was a high volume HIIT intervention on young,
healthy but inactive predominantly Caucasian adults,
and included a nutrition intervention. Previous studies
have predominantly investigated endurance interventions, including participants from a mix of nationalities,
and mainly inactive but healthy populations [16]. Moreover, there may be differences in the accuracy of findings
between studies based on participant compliance to
study protocols. These factors may have influenced the
gene expression and the significance of variants discovered in previous research, the validation study and the
Predict-HIIT study. If our study had a larger sample size,
we could have stratified our analysis to see if associations
were different when clustered according to healthy and
clinical populations, and training doses. We tried to combat this by including significant covariates in our GWAS
model, including the individual study.
Despite limited research, the declining cost of genetic
testing has created an abundance of direct-to-consumer
(DTC) DNA testing companies [71]. These testing companies often base recommendations on single or very few
genes. For example, Alpha-actinin-3 (ACTN3) is a common ‘fitness gene’ found in many DTC tests, whereby
consumers are encouraged to modify the intensity, volume or frequency of their exercise training to suit their
ACTN3 genotype. Potential ACTN3 ‘genotype-based
training protocols’ for strength and endurance training
improvements have been outlined in previous research
[72]. For V̇O2peak improvement, the authors suggest RR
allele homozygotes and RX allele heterozygotes are resistant to muscle damage and better suited to HIIT; whereas
XX allele homozygotes have lower skeletal muscle function and poorer recovery, and subsequently are better
suited to MICT [72]. Our analysis and other research has
shown that exercise-related phenotypes, such as change
in V̇O2peak response, is a polygenic trait where multiple
genes influence various cellular pathways [3, 14] and each
gene may contribute only a small percentage to the overall change [16, 26, 73]. We have established that the significance of these genes and associated variants remain
uncertain, questioning the importance of genetics in predicting individual response and the validity of commercial tests reliant on limited variants used for personalised
exercise prescription.
An even larger study with more participants is needed
to advance this field of research. In other areas of genetic
research, this is achieved by combining datasets and
completing a meta-analysis of many genome-wide association studies. As outlined by Zeggini and Ionnidis
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[74], combining many GWAS datasets would require a
consortium with various institutions and laboratories
combining to develop a robust protocol that addresses
selection bias, quality control, heterogeneity of populations studied and the replication of biologically plausible previous findings. Based on our findings, we have
calculated that at least 2960 participants would need to
be included in well-controlled exercise interventions to
measure V̇O2peak response. Future research should also
focus on more than just the genome by using epigenomics, transcriptomics and metagenomics. Having large
datasets with this information may help to identify with
greater confidence the gene and pathway interactions,
and epigenetic changes resulting from environmental
influences [75]. Analysis of how exercise dose and quantitative traits including diet, sleep, recovery between
training sessions, clinical conditions (e.g. coronary artery
disease, type 2 diabetes) and how the microbiome may
affect epistasis could also be explored. The Athlome Project Consortium is a collaborative initiative between several institutions to find genetic variants associated with
athletic performance [76]. A similar concept could be
developed specifically for finding genetic variants associated with V̇O2peak response in non-athletes to aerobic
training interventions.

Conclusions
In conclusion, we found 12 novel genetic variants associated with V̇O2peak response in the Predict-HIIT study
group. These SNPs have common biological pathways
and processes to previous research findings, but could
not be replicated in a small independent study. Furthermore, cross-validation found the PPS created from the
top-associated SNPS did not show significant correlation with whom was likely to be a responder or nonresponder to exercise training. Heterogeneity and a lack
of power in the discovery (Predict-HIIT) and validation
(Improve-HIIT) cohorts may have prevented lead SNPs
from being reproduced between studies. Our results
highlight the possible risks associated with predictive
scores for complex traits. Larger sample sizes with wellprescribed, controlled and accurately measured exercise
interventions are required to identify rare variants, gene
interactions and epigenetic changes that may influence
gene expression and V̇O2peak response, and to find the
ideal exercise dose to negate non-response. Ongoing
research and validation of current and previous findings
is needed to confirm if genetics does play a large role in
V̇O2peak response variance, and whether genomic predictors for V̇O2peak response trainability can inform evidence-based clinical practice.
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